ALSO NOTED: Ardana meets with potential suitors;Feds go back to basics with AIDS vax research; and much more...

> Ardana has provided an update on it's proposed sale or merger. The company says that it's met with a "significant number of interested parties," and that there is interest among it suitors regarding licensing opportunities for Ardana's products. Release

> About 1,200 Wyeth got pink slips on Wednesday, their jobs eliminated in the drugmaker's previously announced restructuring. Report

> Germany's Stada Arzneimittel says it's checking out potential takeover targets, looking to continue its recent series of acquisitions. Report

> After trying and failing repeatedly to develop an AIDS vaccine, federal officials say they're going back to the drawing board to come up with some new ideas. Report

> Looking for hard evidence that the FDA is tightening approval standards? Here it is. The agency today proposed tougher clinical trial guidelines for drug-coated stents. Report

> It was a busy day yesterday for FDA safety reviews, with a trifecta of announcements raising questions about drugs for everything from allergies to HIV. Report

Most popular this week: Big Biotech's Stock Report. Article

And Finally... Dr. Andrew Wakefield and two colleagues began their defense against charges that they violated ethics guidelines in the U.K. while developing a 1998 paper that linked autism to vaccines. That study raised a hue and cry around the world that has yet to completely die down, even after a raft of studies now conclude that there is no link. Report

Suggested Articles

Vital strategies for steriles development to ensure more flexibility within drug development.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.